Correlation of Pre-treatment FDG Uptake to Therapeutic Response and Relapse in Patients with Small Cell Lung Cancer
![]() |
Seo, Young-Soon
(Departments of Nuclear Medicine, Chonnam National University Medical School)
Kwon, Seong-Young (Departments of Nuclear Medicine, Chonnam National University Medical School) Jeong, Shin-Young (Departments of Nuclear Medicine, Chonnam National University Medical School) Song, Ho-Chun (Departments of Nuclear Medicine, Chonnam National University Medical School) Min, Jung-Joon (Departments of Nuclear Medicine, Chonnam National University Medical School) Kim, Kyu-Sik (Departments of Pulmonology, Chonnam National University Medical School) Kim, Young-Chul (Departments of Pulmonology, Chonnam National University Medical School) Bom, Hee-Seung (Departments of Nuclear Medicine, Chonnam National University Medical School) |
1 | Payne D, Naruke T. Lung cancer. In: Pollock RE, Manual of clinical oncology, 7th ed. New York: Wiley; 1999:385-405 |
2 | Francis IR, Brown RK, Avram AM. The clinical role of CT/PET in oncology: an update. Cancer Imaging 2005;5:S68-75 DOI |
3 |
Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, et al. Value of |
4 |
Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. |
5 | Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151-9 DOI ScienceOn |
6 | Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-60 DOI ScienceOn |
7 | Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96 DOI ScienceOn |
8 | Wieder HA, Brcher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8 DOI ScienceOn |
9 | Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-74 DOI |
10 | Messa C, Bettinardi V, Picchio M, Pelosi E, Landoni C, Gianolli L, Gilardi MC, et al. PET/CT in diagnostic oncology. Q J Nucl Med Mol Imaging 2004;48:66-75 |
11 |
Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [ |
12 | Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, et al. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci 2006;97:1291-7 DOI ScienceOn |
13 | Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 2006;33:263-9 DOI |
14 | Sing T, Wu F, Brodiin O, Fasth KJ, Langstrom B, Bergstrom M. In vitro PET evaluation in lung cancer cell lines. Anticancer Res 2000;20:1375-80 |
15 | von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238: 405-22 DOI ScienceOn |
16 | Hellwig D, Groschel A, Graeter TP, Hellwig AP, Nestle U, Schafers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21 DOI |
17 | Hellwig D, Graeter TP, Ukena D, Georg T, Kirsch CM, Schafers HJ. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. Thorac Cardiovasc Surg 2004 ;128:892-9 DOI |
18 |
Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, et al. Preoperative |
19 | Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using [(18)F]-fluorodeoxy- D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88 DOI |
20 | Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986;46: 4189-94 |
21 |
Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [ |
22 | Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6 DOI |
23 |
Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. Repeat |
24 | Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005;41:1533-41 DOI ScienceOn |
25 | Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006;107:2468-73 DOI ScienceOn |
26 | Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small cell lung cancer preliminary experience. Am J Clin Oncol 2004;27:164-71 DOI ScienceOn |
27 | Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-33 DOI ScienceOn |
28 | Coleman RE. Clinical PET in Oncology. Clin Positron Imaging 1998;1:15-30 DOI ScienceOn |
29 | Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, et al. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res 2006; 15:4232-6 |
30 | Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F, et al. Prophylactic cranial irradiation in small cell lung cancer: a systemic review of the literature with meta-analysis. BMC cancer 2001;1:5 DOI |
31 | S.-J. Kim, S.-k. Kim, E. S. Lee, J. Ro & S. h. Kang. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352-1357 DOI ScienceOn |
32 | Mountain CF. Revision in the international system for staging lung cancer. Chest 1997;111:1710-7 DOI ScienceOn |
33 | Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001;42:1605-13 |
34 | Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 1991;63:986-92 DOI ScienceOn |
35 | Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of F-18-FDG-PET on the primary staging of small cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-20 DOI |
36 | Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, Eaton W, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989; 7:344-54 DOI |
![]() |